{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:29:34Z","timestamp":1791163774101,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.neurobiolaging.2009.03.004","type":"journal-article","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T04:15:24Z","timestamp":1239768924000},"page":"443-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["NEW evidences for fractalkine\/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease"],"prefix":"10.1016","volume":"32","author":[{"given":"Sun","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tang","family":"Hong-Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao","family":"Jun-Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tang","family":"Yan-Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yun-Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wen-Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Xiang-Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Guo-Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Ya-Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hua-Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Ding-Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0166-2236(99)01453-8","article-title":"Chemokines in the CNS: plurifunctional mediators in diverse states","volume":"22","author":"Asensio","year":"1999","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib2","doi-asserted-by":"crossref","first-page":"10558","DOI":"10.1523\/JNEUROSCI.1799-06.2006","article-title":"Alpha-synuclein expression modulates microglial activation phenotype","volume":"26","author":"Austin","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib3","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1046\/j.1471-4159.2002.01091.x","article-title":"Characterization of chemokines and their receptors in the central nervous system: physiopathological implications","volume":"82","author":"Bajetto","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib4","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1523\/JNEUROSCI.21-17-06480.2001","article-title":"Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity","volume":"21","author":"Bal-Price","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0006-8993(02)02567-2","article-title":"Progressive alteration of neuronal dopamine transporter activity in a rat injured by an intranigral injection of MPP+","volume":"941","author":"Barc","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","article-title":"Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease","volume":"65","author":"Blum","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nn1715","article-title":"Control of microglial neurotoxicity by the fractalkine receptor","volume":"9","author":"Cardona","year":"2006","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0361-9230(95)00019-B","article-title":"l-DOPA metabolism in cortical and striatal tissues in an animal model of Parkinsonism","volume":"37","author":"Carey","year":"1995","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib9","doi-asserted-by":"crossref","first-page":"RC87","DOI":"10.1523\/JNEUROSCI.20-15-j0004.2000","article-title":"Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage","volume":"20","author":"Chapman","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib10","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1046\/j.1460-9568.2002.01938.x","article-title":"Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging","volume":"15","author":"Cicchetti","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib11","doi-asserted-by":"crossref","first-page":"23799","DOI":"10.1074\/jbc.273.37.23799","article-title":"Identification of CX(3)CR1\u2014a chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1","volume":"273","author":"Combadiere","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/13550280290100950","article-title":"Fractalkine (CX3CL1) and brain inflammation: implications for HIV-1-associated dementia","volume":"8","author":"Cotter","year":"2002","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib14","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1212\/WNL.45.12.2143","article-title":"Prevalence of Parkinson's disease in the elderly: the Rotterdam Study","volume":"45","author":"de Rijk","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0378-4274(02)00428-9","article-title":"Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease","volume":"139","author":"Eberhardt","year":"2003","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0165-5728(03)00117-6","article-title":"Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia","volume":"138","author":"Erichsen","year":"2003","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/1521-4141(200001)30:1<87::AID-IMMU87>3.0.CO;2-7","article-title":"Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human","volume":"30","author":"Foussat","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.taap.2003.12.022","article-title":"Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats","volume":"196","author":"Goralski","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib19","doi-asserted-by":"crossref","first-page":"10896","DOI":"10.1073\/pnas.95.18.10896","article-title":"Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia","volume":"95","author":"Harrison","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jnr.10304","article-title":"Fractalkine and fractalkine receptors in human neurons and glial cells","volume":"69","author":"Hatori","year":"2002","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib21","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.parkreldis.2004.10.013","article-title":"Neuroinflammatory processes in Parkinson's disease","volume":"11","author":"Hirsch","year":"2005","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/glia.10037","article-title":"Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS","volume":"37","author":"Hughes","year":"2002","journal-title":"Glia"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1742-2094-4-2","article-title":"Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein","volume":"4","author":"Jin","year":"2007","journal-title":"J. Neuroinflam."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib24","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1128\/MCB.20.11.4106-4114.2000","article-title":"Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion","volume":"20","author":"Jung","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/BF02980066","article-title":"Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells","volume":"27","author":"Kim","year":"2004","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/emm.2006.40","article-title":"Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease","volume":"38","author":"Kim","year":"2006","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.neurobiolaging.2006.11.013","article-title":"Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia","volume":"29","author":"Klegeris","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0091-3057(93)90481-8","article-title":"Central and peripheral minocycline suppresses motor-activity in rats","volume":"44","author":"Kofman","year":"1993","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0162-3109(98)00022-8","article-title":"Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"39","author":"Kohutnicka","year":"1998","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib30","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib31","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F","article-title":"Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure","volume":"46","author":"Langston","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2004.11.012","article-title":"Fractalkine-upregulated milk-fat globule EGF factor-8 protein in cultured rat microglia","volume":"160","author":"Leonardi-Essmann","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jpain.2005.02.001","article-title":"Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain","volume":"6","author":"Lindia","year":"2005","journal-title":"J. Pain"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib34","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.4049\/jimmunol.163.3.1628","article-title":"Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia","volume":"163","author":"Maciejewski-Lenoir","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib35","article-title":"Microglial responses to dopamine in a cell culture model of Parkinson's disease","author":"Mastroeni","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib36","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib37","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1046\/j.1471-4159.1999.0732469.x","article-title":"Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic\/ventral mesencephalic co-cultures","volume":"73","author":"McNaught","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib38","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1111\/j.1460-9568.2005.04470.x","article-title":"An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine","volume":"22","author":"Milligan","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib39","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/j.1460-9568.2004.03709.x","article-title":"Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats","volume":"20","author":"Milligan","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0301-0082(97)00052-X","article-title":"Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide","volume":"54","author":"Minghetti","year":"1998","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib41","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2174\/1381612053381620","article-title":"Inflammatory process in Parkinson's disease: role for cytokines","volume":"11","author":"Nagatsu","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0014-5793(98)00583-3","article-title":"Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?","volume":"429","author":"Nishiyori","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib43","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/0197-4580(95)02012-8","article-title":"Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys","volume":"16","author":"Ovadia","year":"1995","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib44","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1016\/j.febslet.2006.06.087","article-title":"Fractalkine and minocycline alter neuronal activity in the spinal cord dorsal horn","volume":"580","author":"Owolabi","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib45","series-title":"The Rat Brain in Stereotaxic Coordinates, Compact","author":"Paxinos","year":"1997"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib46","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1124\/jpet.103.052407","article-title":"Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy","volume":"306","author":"Raghavendra","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib47","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1460-9568.2004.03514.x","article-title":"Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS","volume":"20","author":"Raghavendra","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib48","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2006-06-026997","article-title":"Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome","volume":"109","author":"Ramos","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0074-7742(07)82010-1","article-title":"Chemokines and chemokine receptors: multipurpose players in neuroinflammation","volume":"82","author":"Ransohoff","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib50","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nn0706-859","article-title":"Fractalkine: moving from chemotaxis to neuroprotection","volume":"9","author":"Re","year":"2006","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.gastro.2006.10.010","article-title":"Enhanced recruitment of CX3CR1+T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease","volume":"132","author":"Sans","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib52","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/ard.2005.051276","article-title":"Soluble fractalkine in the cerebrospinal fluid of patients with neuropsychiatric lupus","volume":"65","author":"Sato","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0167-5699(97)84655-5","article-title":"Fractalkine\u2014a strange attractor in the chemokine landscape","volume":"18","author":"Schall","year":"1997","journal-title":"Immunol. Today"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib54","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00441-004-0938-y","article-title":"Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP","volume":"318","author":"Schober","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbrc.2007.04.100","article-title":"Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases","volume":"358","author":"Schulte","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib56","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0168-0102(01)00254-1","article-title":"Parkinson disease: etiology, pathogenesis and future of gene therapy","volume":"41","author":"Shastry","year":"2001","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/glia.20220","article-title":"Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity","volume":"52","author":"Shie","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib58","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.pbb.2006.05.017","article-title":"Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine","volume":"84","author":"Sindhu","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib59","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0197-4580(99)00066-4","article-title":"Increased microglial activation and protein nitration in white matter of the aging monkey","volume":"20","author":"Sloane","year":"1999","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molbrainres.2004.09.017","article-title":"The MPTP model of Parkinson's disease","volume":"134","author":"Smeyne","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0165-5728(02)00033-4","article-title":"Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury","volume":"125","author":"Soriano","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib62","doi-asserted-by":"crossref","first-page":"1474\u2212+","DOI":"10.1096\/fj.02-0216fje","article-title":"Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease","volume":"16","author":"Sriram","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib63","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1471-4159.2005.03566.x","article-title":"Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha","volume":"96","author":"Sriram","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib64","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C","article-title":"Cytotoxic and genotoxic potential of dopamine","volume":"55","author":"Stokes","year":"1999","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib65","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/1567205053585765","article-title":"Role of fractalkine (CX3CL1) in regulating neuron\u2013microglia interactions: development of viral-based CX3CR1 antagonists","volume":"2","author":"Streit","year":"2005","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib66","article-title":"Synuclein activates microglia in a model of Parkinson's disease","author":"Su","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib67","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0006-8993(02)04085-4","article-title":"Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL\/6 mice","volume":"964","author":"Sugama","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib68","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pain.2006.09.035","article-title":"New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monoarthritis","volume":"129","author":"Sun","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1742-2094-2-17","article-title":"CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin","volume":"2","author":"Sunnemark","year":"2005","journal-title":"J. Neuroinflam."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/jnr.10645","article-title":"Fractalkine protein localization and gene expression in mouse brain","volume":"73","author":"Tarozzo","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib71","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1046\/j.1460-9568.2002.02007.x","article-title":"Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat","volume":"15","author":"Tarozzo","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mds.10332","article-title":"Pathogenic role of glial cells in Parkinson's disease","volume":"18","author":"Teismann","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib73","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.4049\/jimmunol.166.12.7527","article-title":"Minocycline provides neuroprotection against N-methyl-d-aspartate neurotoxicity by inhibiting microglia","volume":"166","author":"Tikka","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib74","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","article-title":"Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system","volume":"367","author":"Ungerstedt","year":"1971","journal-title":"Acta Physiol. Scand. Suppl."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib75","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.neurobiolaging.2003.12.010","article-title":"Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra","volume":"25","author":"van Muiswinkel","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib76","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/j.1460-9568.2004.03593.x","article-title":"Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions","volume":"20","author":"Verge","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-2094-3-6","article-title":"Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease","volume":"3","author":"Vijitruth","year":"2006","journal-title":"J. Neuroinflam."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib78","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.neurobiolaging.2006.11.017","article-title":"Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice","volume":"29","author":"Wakamatsu","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib79","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.neuropharm.2006.05.024","article-title":"Inhibition of tetanically sciatic stimulation-induced LTP of spinal neurons and Fos expression by disrupting glutamate transporter GLT-1","volume":"51","author":"Wang","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib80","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.expneurol.2006.02.002","article-title":"Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+)","volume":"200","author":"Yazdani","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib81","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0197-4580(01)00258-5","article-title":"Phenotypic and functional changes in glial cells as a function of age","volume":"23","author":"Yu","year":"2002","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib82","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/glia.20532","article-title":"Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein","volume":"55","author":"Zhang","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib83","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.04-2751com","article-title":"Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease","volume":"19","author":"Zhang","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.neurobiolaging.2009.03.004_bib84","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pain.2004.12.022","article-title":"ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model","volume":"114","author":"Zhuang","year":"2005","journal-title":"Pain"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458009000980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458009000980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:19:19Z","timestamp":1759317559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458009000980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0197458009000980"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2009.03.004","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NEW evidences for fractalkine\/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2009.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}